Kimberly J Popovits
CIK 1333482 · Interim CEO · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GHDX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
REDWOOD CITY, CA 94063
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | Director | 20,706 | $15.43 | $319.5K | $0 | 1 | 2026-06-22 |
| TXG | Director | 37,445 | $65.87 | $2.47M | $0 | 8 | 2026-06-08 |
| KNSA | Director | 15,345 | $94.40 | $1.45M | $0 | 10 | 2026-06-02 |
| RYTM | Director | — | $113.46 | — | $0 | 1 | 2026-04-03 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 9,656 | $104.91 | $1.01M | $0 | 3 | 2026-03-23 |
| Talis Biomedical Corp (TLIS) Delisted | Interim CEO | 7,855 | $2.84 | $22.3K | $84.8K | 4 | 2023-06-12 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 2,300 | — | — | $0 | 7 | 2020-06-23 |
| GENOMIC HEALTH INC (GHDX) Delisted | President and CEO | 104,436 | — | — | -$41.74M | 109 | 2019-10-09 |
| ZS Pharma, Inc. (ZSPH) Delisted | Director | — | — | — | $0 | 1 | 2015-06-25 |
Recent Filings · Page 14 of 15
150 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2010-09-16 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | — | -$94.5K | EDGAR |
| 2010-08-19 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | — | -$97.5K | EDGAR |
| 2010-05-18 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | — | -$103.2K | EDGAR |
| 2010-04-15 | GENOMIC HEALTH INC (GHDX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-04-13 | GENOMIC HEALTH INC (GHDX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-03-16 | GENOMIC HEALTH INC (GHDX) Delisted | Sell (S) | −20,000 | -$389.1K | EDGAR |
| 2010-02-22 | GENOMIC HEALTH INC (GHDX) Delisted | Mixed | −3,850 | $0 | EDGAR |
| 2009-12-16 | GENOMIC HEALTH INC (GHDX) Delisted | Sell (S) | −5,000 | -$102.0K | EDGAR |
| 2009-11-17 | GENOMIC HEALTH INC (GHDX) Delisted | Sell (S) | −20,000 | -$384.2K | EDGAR |
| 2009-10-15 | GENOMIC HEALTH INC (GHDX) Delisted | Sell (S) | −5,000 | -$102.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.